RICHMOND, Calif.–(BUSINESS WIRE)–BioAge Labs, a clinical-stage biotechnology company developing therapeutics that target the molecular causes of aging to extend healthy human lifespan, today announced the appointment of BJ Sullivan, Ph.D., as Chief Strategy Officer. Sullivan is the first to hold the position at BioAge.
“I am thrilled to announce the promotion of BJ Sullivan to BioAge’s first Chief Strategy Officer. During his time at BioAge, BJ has cultivated a profound understanding of the commercial opportunities and challenges in treating age-related diseases, and leveraged these insights to build out corporate strategy functions that are vital to our success,” said Kristen Fortney, Ph.D., CEO and co-founder of BioAge. “As we expand our portfolio of clinical programs, BJ’s expertise, strategic vision and dedication to our mission will help shape our growth, and ensure our therapies can achieve their full potential.”
Prior to this role, Sullivan served as Chief of Staff and Vice President, Strategy & Business Operations at BioAge. In that capacity, he partnered closely with the executive team to define both corporate and program strategy.
“We are at the beginning of a reimagination of healthcare in an aging world, with focus shifting from managing illness to optimizing healthspan,” Sullivan said. “BioAge’s human-first platform provides unique visibility into aging biology, enabling us to decode and target the pathways that drive the most devastating aspects of aging, including loss of brain, muscle, and immune function. It is a privilege to support BioAge in navigating the many opportunities that emerge as we pioneer the first aging-focused therapeutics. I am eager to continue collaborating with Kristen and the whole BioAge team to advance our pipeline and create transformative medicines to redefine the experience of growing older.”
Sullivan brings extensive experience in biopharma strategy. Before joining BioAge, he was a consultant in the Life Sciences practice at L.E.K. Consulting, a global management consulting firm, where he advised clients ranging from emerging biotechs to Fortune 100 pharmaceutical companies on growth strategy and M&A.
Sullivan holds a Ph.D. in Molecular & Medical Pharmacology from the David Geffen School of Medicine at UCLA, where his graduate work was published in Cell. He also holds an AB in Molecular Biology from Princeton University.
About BioAge Labs, Inc.
BioAge is a clinical-stage biotechnology company developing a pipeline of treatments to extend healthy lifespan by targeting the molecular causes of aging. The company uses its discovery platform, which combines quantitative analysis of proprietary longitudinal human samples with detailed health records to map out the key molecular pathways that impact healthy human aging. By targeting the mechanisms of aging with a large and mechanistically diverse portfolio of drugs, BioAge is unlocking opportunities to treat or even prevent age-related disease in entirely new ways. BioAge’s growing portfolio includes multiple assets targeting muscle, immune, and brain aging. To date, BioAge has raised $127M from Andreessen Horowitz, Kaiser Foundation Hospitals, and others.
